Transcranial magnetic stimulation for major depressive disorder: a pragmatic approach to implementing TMS in a clinical practice.

Another option for managing major depressive disorder (MDD) became available in October 2008 with the Food and Drug Administration's (FDA) market clearance of NeuroStar TMS (transcranial magnetic stimulation) Therapy System. A panel of psychiatrists who have been treating patients with NeuroStar TMS Therapy in their clinics assembled for a virtual roundtable discussion regarding their experiences. In this supplement, the panel addresses the following issues: the FDA-cleared indication for use of NeuroStar TMS Therapy; logistic and staffing considerations in the outpatient setting; selecting the right patient for TMS Therapy; talking with patients and family about TMS Therapy. To give the overview a meaningful context, each panelist shares a personal account of a patient case, describing the treatment course and outcomes achieved with TMS Therapy.